Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

IMV Inc IMVIF

IMV Inc. is a Canada-based company. The Company has no business operations.


GREY:IMVIF - Post by User

Post by Breakthoroughon Sep 10, 2022 3:43pm
448 Views
Post# 34954448

Interesting (and hidden) data

Interesting (and hidden) dataIf you go to page 19 of last Corporate presentation, you will find, on the left side, "Further evaluating data from SPIReL" (Phase 2a of DLBCL, being Phase 2b the VITALIZE TRIAL). There you can see something not announced till now: mOS In PD-L1+ patients of 17'4 months. That's REALLY GOOD. To have an idea, think that CAR T has generally a mOS of 12 months in the trials (f.ex. JULIET Trial), and 15'8 months in this study of patients treated with commercial CAR T: https://ashpublications.org/bloodadvances/article/4/19/4669/463994/Outcomes-in-patients-with-DLBCL-treated-with Mvp-S+KTR is, needless to say, administered AGTER CAR T (or to people not eligible for CAR T, if I remember well)
<< Previous
Bullboard Posts
Next >>